Therapeutic Implications and Comprehensive Insights into Cellular Senescence and Aging in the Tumor Microenvironment of Sarcoma

Overview

Journal Discov Oncol

Publisher Springer

Date 2025 Jan 15

PMID 39812903

Authors

Pengfei Zan

Yi Zhang

Yidong Zhu

Qingjing Chen

Zhengwei Duan

Yonghao Guan

Kaiyuan Liu

Anquan Shang

Zihua Li

Affiliations

Soon will be listed here.

Abstract

Sarcoma (SARC), a diverse group of stromal tumors arising from mesenchymal tissues, is often associated with a poor prognosis. Emerging evidence indicates that senescent cells within the tumor microenvironment (TME) significantly contribute to cancer progression and metastasis. Although the influence of senescence on SARC has been partially acknowledged, it has yet to be fully elucidated. In this study, we revealed that senescence level and age were associated with TME, immune treatment indicators, and prognosis in SARC. Utilizing the weighted gene co-expression network analysis and least absolute shrinkage and selection operator algorithm, we identified senescence-related genes and developed a senescence predictor. Three genes, RAD54, PIK3IP1, and TRIP13, were selected to construct a multiple linear regression model. Validation cohorts, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction confirmed that the predictor derived from these three genes possessed prognostic and pathological relevance. Our senescence predictor provides comprehensive insights into the molecular mechanisms of SARC and identifies potential biomarkers for prognosis, paving the way for effective treatments. The results of this study hold promise for developing therapeutic strategies tailored to the unique characteristics of SARC.

References

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Hayflick L . THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res. 1965; 37:614-36. DOI: 10.1016/0014-4827(65)90211-9. View

Muchnik E, Loh K, Strawderman M, Magnuson A, Mohile S, Estrah V . Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. J Am Geriatr Soc. 2019; 67(5):905-912. PMC: 7814272. DOI: 10.1111/jgs.15750. View

Lopez S, Lim E, Horswell S, Haase K, Huebner A, Dietzen M . Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat Genet. 2020; 52(3):283-293. PMC: 7116784. DOI: 10.1038/s41588-020-0584-7. View

Wang X, Ma L, Pei X, Wang H, Tang X, Pei J . Comprehensive assessment of cellular senescence in the tumor microenvironment. Brief Bioinform. 2022; 23(3). PMC: 9116224. DOI: 10.1093/bib/bbac118. View

Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P . Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020; 12(1):21. PMC: 7045518. DOI: 10.1186/s13073-020-0721-z. View

Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J . Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021; 36(8):109599. PMC: 8757482. DOI: 10.1016/j.celrep.2021.109599. View

Campisi J . Aging, cellular senescence, and cancer. Annu Rev Physiol. 2012; 75:685-705. PMC: 4166529. DOI: 10.1146/annurev-physiol-030212-183653. View

10.

Jing S, Zhao L, Zhao L, Gao Y, He T . TRIP13: A promising cancer immunotherapy target. Cancer Innov. 2024; 3(6):e147. PMC: 11467489. DOI: 10.1002/cai2.147. View

11.

Hoenicke L, Zender L . Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies. Carcinogenesis. 2012; 33(6):1123-6. DOI: 10.1093/carcin/bgs124. View

12.

Mun J, Baek S, Park W, Kim W, Kim S, Roh Y . E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. Int J Mol Sci. 2020; 21(23). PMC: 7730422. DOI: 10.3390/ijms21239025. View

13.

Skoda J, Veselska R . Cancer stem cells in sarcomas: Getting to the stemness core. Biochim Biophys Acta Gen Subj. 2018; 1862(10):2134-2139. DOI: 10.1016/j.bbagen.2018.07.006. View

14.

Agarwal S, Busse P . Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol. 2010; 104(3):183-90. DOI: 10.1016/j.anai.2009.11.009. View

15.

Gorgoulis V, Adams P, Alimonti A, Bennett D, Bischof O, Bishop C . Cellular Senescence: Defining a Path Forward. Cell. 2019; 179(4):813-827. DOI: 10.1016/j.cell.2019.10.005. View

16.

Anderson J, Denny C, Tap W, Federman N . Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012; 72(2):112-21. PMC: 4283808. DOI: 10.1038/pr.2012.54. View

17.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

18.

Partridge A, Hughes M, Warner E, Ottesen R, Wong Y, Edge S . Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016; 34(27):3308-14. DOI: 10.1200/JCO.2015.65.8013. View

19.

Chatsirisupachai K, Lesluyes T, Paraoan L, Van Loo P, de Magalhaes J . An integrative analysis of the age-associated multi-omic landscape across cancers. Nat Commun. 2021; 12(1):2345. PMC: 8058097. DOI: 10.1038/s41467-021-22560-y. View

20.

Hernandez-Segura A, Nehme J, Demaria M . Hallmarks of Cellular Senescence. Trends Cell Biol. 2018; 28(6):436-453. DOI: 10.1016/j.tcb.2018.02.001. View